Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625001151426
Ethics application status
Approved
Date submitted
9/10/2025
Date registered
21/10/2025
Date last updated
28/05/2026
Date data sharing statement initially provided
21/10/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
High dose palliative radiotherapy in patients with metastatic malignancy who cannot or will not have standard of care such as chemotherapy or other drug treatment
Query!
Scientific title
Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy
Query!
Additional trial identifiers [1]
315540
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
HD-PRiMe
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
metastatic cancer
339146
0
Query!
metastatic malignancy
339147
0
Query!
oesophageal cancer
339148
0
Query!
pancreatic cancer
339149
0
Query!
head and neck cancer
339150
0
Query!
cutaneous squamous cell carcinoma
339151
0
Query!
colorectal cancer
339152
0
Query!
bladder cancer
339153
0
Query!
triple-negative breast cancer
339154
0
Query!
non-small cell lung cancer
339155
0
Query!
skin cancer
339156
0
Query!
Condition category
Condition code
Cancer
335432
335432
0
0
Query!
Bladder
Query!
Cancer
335433
335433
0
0
Query!
Bowel - Anal
Query!
Cancer
335434
335434
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Cancer
335435
335435
0
0
Query!
Breast
Query!
Cancer
335436
335436
0
0
Query!
Cervical (cervix)
Query!
Cancer
335437
335437
0
0
Query!
Head and neck
Query!
Cancer
335438
335438
0
0
Query!
Kidney
Query!
Cancer
335439
335439
0
0
Query!
Lung - Non small cell
Query!
Cancer
335440
335440
0
0
Query!
Pancreatic
Query!
Cancer
335441
335441
0
0
Query!
Oesophageal (gullet)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Patients will receive standard doses of high-dose palliative radiotherapy to sites of metastatic disease until all known sites of disease have been treated.
Each treatment course will consist of 5 treatments delivered 2-3x per week over the course of 2 weeks. Up to six sites of disease will be treated concurrently. If required, further sites will be treated after a four week break with this process repeated until all known disease has been treated. Radiotherapy dose and fractionation will be between 20Gy-30Gy in 5 fractions depending on location and size of tumour. There is no maximum number of treatment courses set that can be delivered to patients. There is a minimum of 1 treatment course. Patients will be asked to undergo one or multiple different types of CT scans and/or a PET scan to assess the impact of radiotherapy on the metastases. The treating clinician will then determine if further treatment is required.
Patients will have radiotherapy planning performed approximately 2 weeks prior to radiotherapy treatment. Treatment will be delivered in line with standard practice at Sunshine Coast University Hospital and will be overseen by a Senior Radiation Oncologist. Adherence will be monitored by review of electronic medical records.
Query!
Intervention code [1]
332166
0
Treatment: Devices
Query!
Intervention code [2]
332167
0
Treatment: Other
Query!
Description of the comparator or control
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
343005
0
Recruitment rate and proportion of patients receiving high dose palliative radiotherapy in patients with newly diagnosed de novo metastatic malignancy or for patients with metastatic malignancy with disease progression on systemic therapy.
Query!
Assessment method [1]
343005
0
Assessed as a composite primary outcome. Review of patient screening and electronic medical records.
Query!
Timepoint [1]
343005
0
Interim analysis at 12 months from study commencement Second interim analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Query!
Secondary outcome [1]
453107
0
Progressional-free survival (PFS)
Query!
Assessment method [1]
453107
0
Restaging CT-CAP +/- CT-B +/- CT-N (whole-body PET-CT may be used if clinically relevant). Review of electronic medical records
Query!
Timepoint [1]
453107
0
First analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Query!
Secondary outcome [2]
453108
0
New metastasis-free survival (NMFS)
Query!
Assessment method [2]
453108
0
Restaging CT-CAP +/- CT-B +/- CT-N (whole-body PET-CT may be used if clinically relevant). Review of electronic medical records
Query!
Timepoint [2]
453108
0
First analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Query!
Secondary outcome [3]
453109
0
Overall survival (OS)
Query!
Assessment method [3]
453109
0
Review of electronic medical records
Query!
Timepoint [3]
453109
0
First analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Query!
Secondary outcome [4]
453110
0
Clinician reported acute radiotherapy-related toxicity
Query!
Assessment method [4]
453110
0
Common terminology criteria for adverse events (CTCAE) v5.0
Query!
Timepoint [4]
453110
0
Interim analysis at 12 months from study commencement Second interim analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Query!
Secondary outcome [5]
453111
0
Patient reported quality of life (QoL)
Query!
Assessment method [5]
453111
0
European Organisation for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-c30)
Query!
Timepoint [5]
453111
0
Interim analysis at 12 months from study commencement Second interim analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Query!
Eligibility
Key inclusion criteria
Aged 18 years or more.
Able to give informed consent.
Metastatic cancer (TxNxM>0 or International Federation of Gynecology and Obstetrics (FIGO) IV) based on staging CT-CAP +/- CT-B +/- CT-N or whole-body PET-CT +/- CT-B.
Burden of disease able to be encompassed within standard organ at risk (OAR) constraints.
Eastern Cooperative Oncology Group (ECOG) status 0-2.
Patient deemed unsuitable for systemic therapy by treating Medical Oncologist OR patient declined systemic therapy offered by Medical Oncologist.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
Patients currently receiving systemic therapy (cytotoxic chemotherapy, immunotherapy, biologic, hormone, or molecularly targeted therapy).
Patients with metastatic malignancy with disease progression whilst receiving systemic therapy that do not have a further line of systemic therapy available to them.
Life expectancy <3 months.
Breast (except for triple negative disease), prostate, haematological or primary central nervous system (CNS) malignancies.
Intracranial metastases not suitable for localised treatment (i.e., resection or stereotactic radiotherapy).
Previous radiotherapy precluding treatment of current metastatic sites.
Pregnancy.
Intercurrent illness that will interfere with radiotherapy delivery.
Treatment toxicity expected to reduce QoL significantly e.g., treatment to bilateral parotids.
Prior diagnosis of connective tissue disorder.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
3/11/2025
Query!
Actual
9/12/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
90
Query!
Accrual to date
4
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
28620
0
Sunshine Coast University Hospital - Birtinya
Query!
Recruitment postcode(s) [1]
44849
0
4575 - Birtinya
Query!
Funding & Sponsors
Funding source category [1]
320139
0
Hospital
Query!
Name [1]
320139
0
Sunshine Coast University Hospital
Query!
Address [1]
320139
0
Query!
Country [1]
320139
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Sunshine Coast University Hospital
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
322701
0
None
Query!
Name [1]
322701
0
Query!
Address [1]
322701
0
Query!
Country [1]
322701
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
318685
0
Metro North Health Human Research Ethics Committee
Query!
Ethics committee address [1]
318685
0
https://metronorth.health.qld.gov.au/research/ethics-and-governance/human-research-ethics-committee
Query!
Ethics committee country [1]
318685
0
Australia
Query!
Date submitted for ethics approval [1]
318685
0
26/06/2021
Query!
Approval date [1]
318685
0
24/08/2021
Query!
Ethics approval number [1]
318685
0
Query!
Summary
Brief summary
This study is trying to determine whether giving palliative radiation therapy to all known sites of cancer in the body for patients with metastatic cancer can slow down the growth of disease, reduce the rate of new sites developing, improve overall survival and/or improve quality of life. Who is it for? You may be eligible for this study if you are aged 18 years or older and have been diagnosed with a metastatic cancer, including oesophageal, pancreatic, head and neck cancer, cutaneous squamous cell carcinoma, colorectal cancer, bladder cancer, triple-negative breast cancer, non-small cell lung cancer and skin cancer and you are not currently undertaking any oral and/or intravenous therapies for your cancer. Study details Participants who choose to enrol in this study will undergo at least one radiotherapy treatment course which will involve attending 5 radiotherapy sessions scheduled 2-3x per week over 2 weeks. Radiotherapy will be delivered to specific sites of the body depending upon each individual's metastases. At the end of the treatment course, participants will be asked to undergo different types of CT scans and/or a PET scan to review the effect of the radiotherapy on the metastases. If required, participants may undergo an additional treatment course of 5 sessions after a four week break. This treatment process will then be repeated until all known cancer sites have been treated. At 12 months, 2 and 3 years after enrolling into the study, participants will also be asked to attend different CT scans and/or PET scan to review their cancer status and will also be asked to complete a questionnaire regarding their quality of life. It is hoped this research will determine whether the use of radiotherapy alone is effective in the treatment of cancer metastases in patients who are not able to receive oral and/or intravenous therapies.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
144934
0
Dr Myo Min
Query!
Address
144934
0
Sunshine Coast University Hospital, 6 Doherty Street Birtinya, QLD, 4575
Query!
Country
144934
0
Australia
Query!
Phone
144934
0
+61 07 5202 8257
Query!
Fax
144934
0
Query!
Email
144934
0
[email protected]
Query!
Contact person for public queries
Name
144935
0
Dr Mark Windsor
Query!
Address
144935
0
Sunshine Coast University Hospital, 6 Doherty Street Birtinya, QLD, 4575
Query!
Country
144935
0
Australia
Query!
Phone
144935
0
+61 07 5202 0651
Query!
Fax
144935
0
Query!
Email
144935
0
[email protected]
Query!
Contact person for scientific queries
Name
144936
0
Dr Myo Min
Query!
Address
144936
0
Sunshine Coast University Hospital, 6 Doherty Street Birtinya, QLD, 4575
Query!
Country
144936
0
Australia
Query!
Phone
144936
0
+61 07 5202 8257
Query!
Fax
144936
0
Query!
Email
144936
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
•
Researchers
•
Participants involved in this research will be able to request access to their de-identified data. All data will be de-identified prior to sharing.
Conditions for requesting access:
•
Yes, conditions apply:
•
Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
•
All de-identified individual participant data
What types of analyses could be done with individual participant data?
•
Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
•
Email of trial custodian, sponsor or committee:
Email of contacts listed on this trial registration as per below:
[email protected]
[email protected]
Are there extra considerations when requesting access to individual participant data?
Yes:
Departmental policies may be an extra consideration when requesting access to individual participant data.
What supporting documents are/will be available?
No Supporting Document Provided
Type
Citation
Link
Email
Other Details
Attachment
Informed consent form
Participant information and consent form can be re...
[
More Details
]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF